From: Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor
GIPAP Enrollment by Age Groups
Age groups
No of patients
< 20
13
21-30
16
31-40
31
41-50
23
51-60
61-70
8
71-80
2
Total
106